anti-Tumor Necrosis Factor Receptor Superfamily, Member 6b, Decoy (TNFRSF6B) Anticorps

Human Tumor Necrosis Factor Receptor Superfamily, Member 6b, Decoy (TNFRSF6B) interaction partners

1. significantly higher levels of TL1A and its decoy receptor DcR3 in RA patients than in controls; TL1A is significantly related to the disease activity and enhances IL-17 production

2. Aberrant expression of DcR3, which is upregulated by oestrogen 25, is an important pathogenic factor in inducing endometriosis.

3. High DCR3 expression is associated with coronary artery disease.

4. Given the differential immune responses and evasion mechanisms in breast cancer, we expect to identify different breast cancer groups based on their expression of immune-related genes. TGF-beta and DcR3 are potential novel drug targets for breast cancer immunotherapy.

5. The combination of decoy receptor 3, soluble urokinase type plasminogen activator receptor, and procalcitonin improved the sensitivity and specificity of diagnosis of sepsis, suggesting that use of the combination of three indexes enhanced the efficiency of sepsis diagnosis.

6. Compared with the control, miR-340 was significantly lower in the serum of hepatocellular carcinoma patients (p<0.01). miR-340 was lower in HCC tissues than in adjacent; however, DcR3, TGF-beta1 and Smad2 were higher.

7. DcR3 treatment caused HepG2 cell cytoskeleton remodeling, inhibited E-cadherin expression, and promoted cell migration.

8. DcR3 gene polymorphisms are associated with sporadic breast infiltrating ductal carcinoma risk in Northeast Chinese females

9. Study found that both transcriptional expression and post-transcriptional DcR3 expression DcR3 expression were significantly up-regulated in colorectal cancer (CRC) tissues. DcR3 was found to be playing a critical role in CRC proliferation and migration in vitro and in tumorigenesis and metastasis in vivo.

10. Higher plasma DcR3 level was related to better coronary collateral circulation (CCC) formation and displayed potent predictive power for CCC status in patients with coronary artery disease.

11. High serum DcR3 levels are associated with disease severity in nonatopic asthma patients.

12. Results show that DcR3 engages TNF ligands: FasL, LIGHT, and TL1A in a structurally similar fashion and its promiscuity is due to recognition of backbone atoms and invariant side chains.

13. These results raise the possibility for involvement of TL1A/DR3/DR3-mediated mechanisms in epithelial-mesenchymal interactions and the development of inflammation-induced intestinal fibrosis in Crohn's disease.

14. when idiopathic pulmonary fibrosis cells interact with collagen matrix, aberrantly activated Akt increases DcR3 expression via GSK-3beta-NFATc1 and protects IPF cells from the FasL-dependent apoptotic pathway.

15. Coexpression of TNFRSF6B and PCDHGA3 was observed immunohistochemically in FL18 cells, suggesting potential cooperation in tumor cell maintenance.

16. Loss of DcR3 impaired the growth and invasive property of HCC cell line of HepG2.

17. Overexpression of DcR3 was significantly related to the risk of female reproductive cancers (OR=10.69, 95% CI: 6.33-18.05), TNM stage (OR=5.51, 95% CI: 2.83-10.71), differentiation (OR=4.16, 95% CI: 2.28-7.60), lymph node metastasis (OR=5.89, 95% CI: 3.16-10.9), age (OR=0.85, 95% CI: 0.51-1.44), and overall survival time (OR=1.84, 95% CI: 0.58-5.83).

18. The serum level of DcR3 may be a useful marker for disease activity in ANCA-associated renal vasculitis.

19. The sDcR3 levels in patients with HIV-1 subtype B were significantly higher than those in patients infected with subtype CRF01_AE. HIV-1 subtype B and slow disease progression were associated with higher levels of sDcR3.

20. DcR3 inhibits influenza a virus-induced JNK and ERK activation in human macrophages